Logo image of CNSP

CNS PHARMACEUTICALS INC (CNSP) Stock Fundamental Analysis

NASDAQ:CNSP - Nasdaq - US18978H3003 - Common Stock - Currency: USD

0.075  -0.01 (-10.5%)

After market: 0.0701 0 (-6.53%)

Fundamental Rating

1

CNSP gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 194 industry peers in the Pharmaceuticals industry. CNSP may be in some trouble as it scores bad on both profitability and health. CNSP does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CNSP had negative earnings in the past year.
In the past year CNSP has reported a negative cash flow from operations.
CNSP had negative earnings in each of the past 5 years.
In the past 5 years CNSP always reported negative operating cash flow.
CNSP Yearly Net Income VS EBIT VS OCF VS FCFCNSP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 -5M -10M -15M

1.2 Ratios

CNSP's Return On Assets of -230.21% is on the low side compared to the rest of the industry. CNSP is outperformed by 91.35% of its industry peers.
Looking at the Return On Equity, with a value of -508.80%, CNSP is doing worse than 82.16% of the companies in the same industry.
Industry RankSector Rank
ROA -230.21%
ROE -508.8%
ROIC N/A
ROA(3y)-463.63%
ROA(5y)-299.92%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CNSP Yearly ROA, ROE, ROICCNSP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 0 500 -500 1K -1K

1.3 Margins

CNSP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CNSP Yearly Profit, Operating, Gross MarginsCNSP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023

More info and screens

3

2. Health

2.1 Basic Checks

CNSP has less shares outstanding than it did 1 year ago.
CNSP has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, CNSP has a worse debt to assets ratio.
CNSP Yearly Shares OutstandingCNSP Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 500K 1M 1.5M
CNSP Yearly Total Debt VS Total AssetsCNSP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M

2.2 Solvency

CNSP has an Altman-Z score of -21.59. This is a bad value and indicates that CNSP is not financially healthy and even has some risk of bankruptcy.
CNSP has a Altman-Z score of -21.59. This is amonst the worse of the industry: CNSP underperforms 87.03% of its industry peers.
CNSP has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
CNSP has a Debt to Equity ratio of 0.01. This is comparable to the rest of the industry: CNSP outperforms 56.22% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -21.59
ROIC/WACCN/A
WACCN/A
CNSP Yearly LT Debt VS Equity VS FCFCNSP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 5M -5M 10M -10M

2.3 Liquidity

A Current Ratio of 1.82 indicates that CNSP should not have too much problems paying its short term obligations.
CNSP has a Current ratio of 1.82. This is in the lower half of the industry: CNSP underperforms 63.24% of its industry peers.
CNSP has a Quick Ratio of 1.82. This is a normal value and indicates that CNSP is financially healthy and should not expect problems in meeting its short term obligations.
CNSP's Quick ratio of 1.82 is in line compared to the rest of the industry. CNSP outperforms 42.16% of its industry peers.
Industry RankSector Rank
Current Ratio 1.82
Quick Ratio 1.82
CNSP Yearly Current Assets VS Current LiabilitesCNSP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M

More info and screens

1

3. Growth

3.1 Past

CNSP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -30.37%.
EPS 1Y (TTM)-30.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.85%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, CNSP will show a very strong growth in Earnings Per Share. The EPS will grow by 25.36% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y92.92%
EPS Next 2Y40.27%
EPS Next 3Y25.36%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CNSP Yearly Revenue VS EstimatesCNSP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M
CNSP Yearly EPS VS EstimatesCNSP Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -200 -400 -600 -800

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CNSP. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CNSP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CNSP Price Earnings VS Forward Price EarningsCNSP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CNSP Per share dataCNSP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60 -80

4.3 Compensation for Growth

CNSP's earnings are expected to grow with 25.36% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.27%
EPS Next 3Y25.36%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CNSP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CNS PHARMACEUTICALS INC

NASDAQ:CNSP (2/20/2025, 8:08:06 PM)

After market: 0.0701 0 (-6.53%)

0.075

-0.01 (-10.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-14 2024-11-14/amc
Earnings (Next)03-31 2025-03-31/amc
Inst Owners0.45%
Inst Owner Change317.96%
Ins Owners0.06%
Ins Owner Change0%
Market Cap5.62M
Analysts82.5
Price Target2.3 (2966.67%)
Short Float %4.88%
Short Ratio0.13
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)350%
PT rev (3m)350%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.68
P/tB 1.68
EV/EBITDA N/A
EPS(TTM)-80.15
EYN/A
EPS(NY)-0.4
Fwd EYN/A
FCF(TTM)-0.19
FCFYN/A
OCF(TTM)-0.19
OCFYN/A
SpS0
BVpS0.04
TBVpS0.04
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -230.21%
ROE -508.8%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-463.63%
ROA(5y)-299.92%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 66.06%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.82
Quick Ratio 1.82
Altman-Z -21.59
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)64.81%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-30.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.85%
EPS Next Y92.92%
EPS Next 2Y40.27%
EPS Next 3Y25.36%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y10.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-23.31%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-23.4%
OCF growth 3YN/A
OCF growth 5YN/A